Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 1/20 | 0.50 |
| ▸ | EDNRA | P25101 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MMP3 | P08254 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 2/20 | 0.43 |
| ▸ | CREB1 | P16220 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8145094 | 0.92 | IDH1 (0.44) | IDH1EDNRALMNAGAAPOLB | |
| SCHEMBL338935 | 0.89 | IDH1 (0.48) | IDH1EDNRALMNAGAAPOLB | |
| SCHEMBL337855 | 0.87 | IDH1 (0.49) | IDH1EDNRALMNAGAAPOLB | |
| SCHEMBL10442342 | 0.85 | EDNRA (0.45) | EDNRALMNAGAAPOLBHPGD | |
| SCHEMBL15910022 | 0.82 | LMNA (0.61) | IDH1LMNAGAAPOLBHPGD | |
| SCHEMBL22872659 | 0.82 | TEAD4 (0.43) | EDNRALMNAGAAHPGDALDH1A1 | |
| SCHEMBL339006 | 0.82 | BRD4 (0.47) | IDH1LMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL13395924 | 0.82 | BRD4 (0.50) | IDH1LMNAGAAHPGDALDH1A1 | |
| SCHEMBL4328309 | 0.82 | LMNA (0.44) | IDH1EDNRALMNAGAAPOLB | |
| SCHEMBL10290056 | 0.81 | EDNRA (0.41) | EDNRALMNAGAAHPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-11 | — | — | US | disclosed |
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-04-11 | — | — | US | disclosed |
| WO-2017156194-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017156194-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20150291618-A1 | CARBAMOYLPYRIDONE DERIVATIVES | CONCERT PHARMACEUTICALS INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20140213553-A1 | CARBAMOYLPYRIDONE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-1687298-B1 | CYCLOALKYL DERIVATIVES OF 3-HYDROXY-4-PYRIDINONES | APOTEX INC (CA) | 2012-12-26 | — | — | EP | disclosed |
| US-8318945-B2 | Metalloprotein inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-11-27 | — | — | US | disclosed |
| US-6506911-B2 | Reacting a 2-(1-hydroxyalkyl)-3-hydroxypyran-4(1H)one compound with benzaldehyde dimethyl acetal to form 8-oxo-4,8-dihydro-2-phenyl-4h(3,2-d)-m-dioxin, reacting it with an amine compound to form an intermediate, then reducing | BTG INTERNATIONAL LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-0984934-B1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNAT LTD COMPANY NO 26 (GB) | 2003-01-08 | — | — | EP | disclosed |
| US-6476229-B1 | Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide | APOTEX, INC. (CA) | 2002-11-05 | — | — | US | disclosed |
| US-6472532-B1 | INEXPENSIVE METHOD USING KOJIC ACID AS SAFE STARTING MATERIAL FOR SYNTHESIS OF ORALLY ACTIVE IRON CHELATORS | APOTEX, INC. (CA) | 2002-10-29 | — | — | US | disclosed |
| US-6448273-B1 | SUCH AS 2,6-DIMETHOXYMETHYL-1-METHYL-3-BENZYLOXPYRIDIN-4(1H)-ONE; TREATING DISORDERS ASSOCIATED WITH IRON DISTRIBUTION AND IRON DEPENDANT PARASITES; REDUCED LEVELS OF ACTIVE AGENT; SELECTIVE TARGETING TO TISSUES AND LIVER; METABOLIC STABILITY | BTG INTERNATIONAL LIMITED (GB) | 2002-09-10 | — | — | US | disclosed |
| US-6426418-B1 | REACTING A 3-OXY-2-HYDROXYALKYL-4H-PYRAN-4-ONE DERIVATIVE WITH SODIUM HYPOCHLORITE SOLUTION, POTASSIUM BROMIDE, TEMPO, AND A PHASE TRANSFER CATALYST TO PRODUCE A 3-OXY-2-CARBOXY-4H-PYRAN-4-ONE DERIVATIVE | APOTEX, INC. (CA) | 2002-07-30 | — | — | US | disclosed |
| US-20020068758-A1 | Novel orally active iron (III) chelators | BTG INTERNATIONAL LIMITED. | 2002-06-06 | — | — | US | disclosed |
| US-6335353-B1 | 3-HYDROXYPYRIDIN-4-ONE DERIVATIVE; IRON DEFICIENCY ANEMIA AND THALASSEMIA TREATMENT | BTG INTERNATIONAL LIMITED (GB) | 2002-01-01 | — | — | US | disclosed |
| EP-0984934-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (Company No. 2664412) (GB) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054138-A1 | NOVEL ORALLY ACTIVE IRON (III) CHELATORS | BTG INTERNATIONAL LIMITED (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213553-A1 | CARBAMOYLPYRIDONE DERIVATIVES | IDH1, CDKN1A, TYMP | IDH1 1/4885EDNRA 4097/4885LMNA 3661/4885 |
| US-20190106398-A1 | COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE | POLRMT, RNASE1, POLM | IDH1 2423/4885EDNRA 4049/4885LMNA 743/4885 |
| US-20020068758-A1 | Novel orally active iron (III) chelators | HAMP, HRH2, GRHPR | IDH1 808/4885EDNRA 467/4885LMNA 2634/4885 |
| US-10889556-B2 | Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease | POLRMT, RNASE1, POLM | IDH1 2423/4885EDNRA 4049/4885LMNA 743/4885 |
| US-20150291618-A1 | CARBAMOYLPYRIDONE DERIVATIVES | CDKN1A, IDH1, IMPDH1 | IDH1 2/4885EDNRA 4091/4885LMNA 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.